AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35940560
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) and Placebo
Trial: 33844449
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg once daily)
Trial: 35972165
Drug: Preoperative 8-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative 8-mg dexamethasone
Trial: 32506738
Drug: Maribavir 100
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir 100 mg
Trial: 32506738
Drug: Maribavir 1200
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir 1200 mg
Trial: 32506738
Drug: Maribavir (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maribavir (both doses)
Trial: 32517564
Drug: Rape myth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rape myth intervention (treatment group)
Trial: 34814766
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment during chemotherapy
Trial: 38488975
Drug: Guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 100 mg every 4 weeks (Q4W)
Trial: 38488975
Drug: Guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 100 mg every 8 weeks (Q8W)
Trial: 33559434
Drug: Acupotomy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupotomy combined with Xingnao Kaiqiao acupuncture therapy
Trial: 33559434
Drug: Xingnao Kaiqiao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnao Kaiqiao acupuncture therapy
Trial: 35970518
Drug: Fluticasone furoate/violanterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/violanterol (FF/VI) 100/25 μg
Trial: 34727465
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Dexamethasone (DXM)
Trial: 32062847
Drug: Administered chemoprophylaxis
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered chemoprophylaxis
Trial: 32062847
Drug: Post-operative VTE
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative VTE dosing
Trial: 32332670
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy at a wavelength of 808 nm, administered twice per week for a total of 12 sessions.
Trial: 32332670
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (simulated laser therapy), administered twice per week for a total of 12 sessions.
Trial: 35684041
Drug: Red orange
RxNorm normalized name: TITANIUM DIOXIDE 2.32 g in 25 g CUTANEOUS CREAM [RED ORANGE JELLY BB SPF20 PA PLUS PLUS NO.1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red orange extract (100 mg/day)
Trial: 35657581
Drug: CC-292 SDD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-292 SDD tablet under fed conditions
Trial: 35657581
Drug: CC-292 SDD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-292 SDD tablet after multiple doses of omeprazole (40 mg)
Trial: 35657581
Drug: CC-292 SDD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-292 SDD formulation (100–300 mg)
Trial: 35657581
Drug: CC-292 under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CC-292 under all conditions
Trial: 35657581
Drug: CC-292 under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CC-292 under fed vs fasted conditions
Trial: 33328269
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg praliciguat
Trial: 33328269
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg praliciguat
Trial: 33451591
Drug: Gabapentin (1800-2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1800-2400 mg/d)
Trial: 33451591
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator (ondansetron 24-32 mg/d or metoclopramide 45-60 mg/d)
Trial: 33004730
Drug: 1% Clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Clotrimazole (antifungal)
Trial: 33963971
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous ascending doses of apitegromab (1, 3, 10, 20, 30 mg/kg)
Trial: 33963971
Drug: Multiple intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intravenous ascending doses of apitegromab (10, 20, 30 mg/kg)
Trial: 33963971
Drug: Single and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple doses of apitegromab
Trial: 33176409
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided continuous lumbar plexus block (LPB) with 0.5% ropivacaine (15 mL)
Trial: 33176409
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural anesthesia (CEA) with 0.5% ropivacaine (15 mL)
Trial: 33051215
Drug: Phenylephrine 1%
RxNorm normalized name: Premier Value Phenylephrine 1% Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 1% and cyclopentolate 0.2% (treatment A)
Trial: 33051215
Drug: Phenylephrine 0.5%
RxNorm normalized name: PHENYLEPHRINE 0.5%/MENTHOL NASAL SPRAY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 0.5% and cyclopentolate 0.1% (treatment B)
Trial: 34794998
Drug: Patient-centred labels
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centred labels (PCL) in low Rapid Estimate of Adult Literacy in Medicine scores
Trial: 34794998
Drug: Standard labels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard labels in low Rapid Estimate of Adult Literacy in Medicine scores
Trial: 32455002
Drug: Cashew nut
RxNorm normalized name: Cashew nut
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cashew nut seed flour (daily intake for 24 weeks)
Trial: 33853492
Drug: Discussed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discussed treatment goals with doctors (450 respondents, 38.9%)
Trial: 33853492
Drug: Not discussed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not discussed treatment goals (287 respondents, 24.8%)
Trial: 33853492
Drug: Anti-RANKL antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-RANKL antibodies
Trial: 34215499
Drug: Aggressive intravenous
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive intravenous hydration (20 ml/kg bolus followed by 3 ml/kg/hr)
Trial: 34215499
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous hydration (10 ml/kg bolus followed by 1.5 ml/kg/hr)
Trial: 34215499
Drug: Aggressive intravenous
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive intravenous hydration in obese patients
Trial: 34215499
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous hydration in obese patients
Trial: 32558773
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LAEF and LAmin volume
Trial: 35440501
Drug: Dapagliflozin and
RxNorm normalized name: Dapagliflozin and metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin and Eplerenone combination
Trial: 34133509
Drug: Levetiracetam (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (titrated from 20 mg/kg/day or 1,000 mg/day up to 60 mg/kg/day or 3,000 mg/day)
Trial: 35232232
Drug: Scientific messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scientific messaging endorsing the vaccine
Trial: 35232232
Drug: Partisan messaging
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Partisan messaging endorsing the vaccine
Trial: 34538401
Drug: Adaptive trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive trial design evaluating multiple agents in RCC
Trial: 34283183
Drug: Canakinumab (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (450 mg for body weight of 40‐<60 kg, 600 mg for 60‐80 kg, and 750 mg for >80 kg; n=227)
Trial: 35724467
Drug: Etoricoxib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (60 mg, Day 1 to Day 8)
Trial: 34006926
Drug: Anlotinib 12
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12 mg orally once daily for 14 days every 3 weeks
Trial: 36346543
Drug: Pharmacist-led intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led intervention involving referral to treating physician for therapy intensification.
Trial: 33576770
Drug: Higher augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher augmentation index
Trial: 33694035
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (first CPAP application on titration night)
Trial: 32676134
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B1 (300 mg tablet) and Gabapentin (300 mg capsules, 3 per day for 4 weeks)
Trial: 36429394
Drug: Medical nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical nutrition therapy/counseling and nutrition education
Trial: 34312823
Drug: Early albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early albumin administration (within the initial 24 perioperative hours)
Trial: 32460840
Drug: Combined group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group-based stabilization and skill-training (SST) intervention added to individual treatment
Trial: 35351194
Drug: Subcutaneous tanezumab
RxNorm normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tanezumab (2.5mg or 5mg every 8 weeks)
Trial: 35351194
Drug: Oral NSAID
RxNorm normalized name: Ansaid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral NSAID (twice daily naproxen, celecoxib, or diclofenac)
Trial: 32192742
Drug: Continuous Transverse
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Transverse Abdominal Plane (TAP) block with ropivacaine 0.375% 20 mL and ropivacaine 0.2%
Trial: 32976869
Drug: Ralimetinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ralimetinib (100 mg/12 h) with chemoradiotherapy (RT 60 Gy in 30 fractions and TMZ 75 mg/m2/day)
Trial: 32976869
Drug: Ralimetinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ralimetinib (200 mg/12 h)
Trial: 32976869
Drug: Ralimetinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ralimetinib (300 mg/12 h)
Trial: 32976869
Drug: Standard concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard concurrent RT and TMZ
Trial: 34620739
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injection into the flexor digitorum brevis and quadratus plantae
Trial: 34620739
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (methylprednisolone) into the plantar fascia
Trial: 36267745
Drug: H-VA (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-VA (high-dose amoxicillin combined with VPZ): VPZ 20 mg b.i.d with amoxicillin 750 mg q.i.d for 7 days
Trial: 36267745
Drug: L-VA (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-VA (low-dose amoxicillin combined with VPZ): VPZ 20 mg b.i.d plus amoxicillin 500 mg q.i.d for 7 days
Trial: 36267745
Drug: VAC (amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC (amoxicillin combined with VPZ and clarithromycin): VPZ 20 mg b.i.d plus amoxicillin 750 mg plus clarithromycin 500 mg for 7 days
Trial: 36811812
Drug: Pridopidine 45
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 45 mg bid
Trial: 35686460
Drug: Caffeine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4 mg/kg) + Acute Intermittent Hypoxia (AIH; FIO2=0.10)
Trial: 35686460
Drug: Caffeine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4 mg/kg) + SHAM (FIO2=0.21)
Trial: 33582533
Drug: Low glycemic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glycemic index diet therapy (LGIT) for 3 months along with ongoing antiepileptic drugs
Trial: 33582533
Drug: Low glycemic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glycemic index diet therapy (LGIT)
Trial: 34329580
Drug: Current approaches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current approaches to risk stratification and treatment of polycythaemia vera
Trial: 35076698
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (CCP) treatment
Trial: 35076698
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no CCP treatment)
Trial: 33219473
Drug: Diagnostic-driven therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic-driven therapy
Trial: 33219473
Drug: ANC <
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANC < 0.1 × 10^9/L
Trial: 33219473
Drug: ANC ≥
RxNorm normalized name: Absolute Neutrophil Count
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANC ≥ 0.1 × 10^9/L
Trial: 32890282
Drug: On-treatment mean
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment mean SBP
Trial: 35487708
Drug: Medicines at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicines at Transition Intervention (MaTI)
Trial: 33892217
Drug: ACT-guided treatment
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-guided treatment
Trial: 35410433
Drug: Lumbrokinase plus
RxNorm normalized name: lumbrokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbrokinase plus aspirin
Trial: 34233378
Drug: 595-nm pulsed
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 595-nm pulsed dye laser (PDL) treatment with oxymetazoline cream
Trial: 34233378
Drug: oxymetazoline cream
RxNorm normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oxymetazoline cream alone
Trial: 35429351
Drug: Mechanical preparation+SE-FS
RxNorm normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical preparation+SE-FS
Trial: 32576228
Drug: 250 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL/day soy milk plus routine treatments
Trial: 32576228
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments only
Trial: 32530412
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with an early warning system for serum creatinine rise, immediate specialist consultation, and issuance of a patient kidney passport.
Trial: 32530412
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (intervention group)
Trial: 36356999
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care treatment for low-risk BCCs.
Trial: 36356999
Drug: Non-treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment arm with close monitoring using multispectral dermoscopy, reflectance confocal microscopy, and high-definition optical coherence tomography.
Trial: 36356999
Drug: Non-treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment arm (control).
Trial: 36356999
Drug: Treatment arm.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm.
Trial: 32149427
Drug: VY‐AADC01 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VY‐AADC01 administration
Trial: 32149427
Drug: Levopoda infusions
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levopoda infusions pre-VY‐AADC01
Trial: 32149427
Drug: Levopoda infusions
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levopoda infusions post-VY‐AADC01
Trial: 32735112
Drug: Ketone Ester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone Ester (KE) 65 g
Trial: 32735112
Drug: Bicarbonate (BIC)
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate (BIC) 300 mg·kg‐1 body weight
Trial: 35429955
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (2 g) administered 1 hour before and 6 hours after ERCP
Trial: 35429955
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) administered 1 hour before and 6 hours after ERCP
Trial: 35429955
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (2 g) in high risk patients
Trial: 35472497
Drug: 40 mm
RxNorm normalized name: Loving Comfort Knee High 30-40 mmHg Beige L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mm Hg INP treatment
Trial: 35472497
Drug: 10 mm
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm Hg INP treatment (sham control)
Trial: 32955174
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (physician's choice of enzalutamide or abiraterone plus prednisone)
Trial: 33504345
Drug: Co-therapy group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-therapy group (DMARDs plus glucocorticoids)
Trial: 33176960
Drug: Locking plate
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locking plate (group L, n = 45)
Trial: 34739974
Drug: Follicular Phase
RxNorm normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Follicular Phase (FP) intervention: quit date set 6-8 days post onset of menses, nicotine replacement therapy transdermal patch for 4 weeks, telephone-based counseling for 6 weeks
Trial: 34739974
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SC): no menstrual timing of quit date, nicotine replacement therapy transdermal patch for 4 weeks, telephone-based counseling for 6 weeks
Trial: 35123461
Drug: Duloxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine treatment for 8 weeks
Trial: 33861440
Drug: Curcumin nanomicelles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin nanomicelles (80 mg/day) + Metformin (500 mg three times daily)
Trial: 34471483
Drug: Proton-pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-pump inhibitor treatment
Trial: 34471483
Drug: Inhalation steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation steroids prescription
Trial: 32185573
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) 2-g in 50 mL physiological saline solution
Trial: 36029105
Drug: Recombinant RBD-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant RBD-based protein subunit vaccine (Noora vaccine) 80 µg
Trial: 36029105
Drug: Recombinant RBD-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant RBD-based protein subunit vaccine (Noora vaccine) 120 µg
Trial: 32991678
Drug: Azithromycin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (20 mg/kg/day) for 7 days
Trial: 32991678
Drug: SXT (trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SXT (trimethoprim 10 mg/kg/day plus sulfamethoxazole 50 mg/kg/day) for 7 days